Johanna Friedl-Naderer, Chief Commercial Officer of Dyne Therapeutics, Inc. (NASDAQ:DYN), filed a Form 4 on September 8, 2026, disclosing two automatic sales of common stock on September 4 and September 8, 2026, both executed to satisfy tax withholding obligations upon the vesting of restricted stock units.

Key Highlights

  • First sale: 900 shares of common stock were disposed of on September 4, 2026, at a weighted average price of $24.35 per share, in a range of $24.29 to $24.50.
  • Second sale: 185 shares were disposed of on September 8, 2026, at a weighted average price of $18.88 per share, in a range of $18.77 to $18.92.
  • RSU origins: The September 4 sale relates to RSUs granted on September 3, 2024; the September 8 sale relates to RSUs granted on December 4, 2024.
  • Post-transaction ownership: Following the September 8 sale, Friedl-Naderer beneficially owned 152,897 shares directly, including 102,966 unvested RSUs.
  • Rule 10b5-1 plan: Both sales were made pursuant to a binding contract satisfying the affirmative defense conditions of Rule 10b5-1(c) and are described as non-discretionary trades.

Automatic Tax-Withholding Sales by Dyne Therapeutics Chief Commercial Officer

According to the filing, Johanna Friedl-Naderer, serving as Chief Commercial Officer of Dyne Therapeutics, Inc., reported two separate dispositions of common stock in her capacity as a Section 16 reporting person. The first transaction, dated September 4, 2026, involved the automatic sale of 900 shares at a weighted average price of $24.35, executed across multiple transactions within the range of $24.29 to $24.50. This sale was connected to the vesting of restricted stock units originally granted on September 3, 2024.

The second transaction, dated September 8, 2026, involved the automatic sale of 185 shares at a weighted average price of $18.88, executed across multiple transactions within the range of $18.77 to $18.92. This sale was tied to RSUs granted on December 4, 2024. The filing states that both automatic sales "do not represent a discretionary trade by the Reporting Person" and are provided for under RSU agreements constituting a "binding contract" consistent with Rule 10b5-1(c).

Following both transactions, the filing reports that Friedl-Naderer directly beneficially owned 152,897 shares of common stock in total, of which 102,966 are identified as unvested RSUs. The Form 4 was signed by Ron Caponigro as Attorney-in-Fact on September 8, 2026. The filing notes that full pricing detail for each transaction within the reported ranges is available upon request from the issuer, any security holder, or SEC staff.

What Was Disclosed

The filing discloses two non-discretionary sales of Dyne Therapeutics common stock by the company's Chief Commercial Officer on September 4 and September 8, 2026, totaling 1,085 shares sold solely to cover tax withholding on vesting RSUs, with 152,897 shares beneficially owned afterward.